‘Restart economy sooner than later’
India is likely to recover faster than the rest of the world from the economic turmoil caused by Covid-19, with new opportunities presenting themselves, says Biocon chairperson.
biocon
April 2020
February 2020
January 2020
October 2019
July 2019
January 2019
November 2018
September 2018
SC agrees to amend order making Covid-19 tests free
An earlier judgment by the apex court making Coronavirus tests free across the board had sparked concerns over the viability of the private sector’s participation in testing for the virus.
Shaw named EY Entrepreneur of the Year
The award recognises entrepreneurs who, with their disruptive ideas and passion for growth, are creating successful global enterprises.
True North invests ₹536 crore in Biocon arm
The private equity firm’s investment values Biocon Biologics at about $3 billion on a pre-money equity basis.
Biocon’s biologics portfolio comes into its own
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
Good blueprint, but gaps remain: India Inc.
Focus on infra, housing, financial services, labour reforms welcome; but concerns remain on corporate tax, ability to meet disinvestment target.
Interim Budget 2019: What Kiran Mazumdar-Shaw expects
Here’s what the Biocon MD and chairperson expects from the interim Budget 2019.
Kiran Mazumdar-Shaw: Grit is her secret formula
Overcoming years of criticism and gender bias, Mazumdar-Shaw has proven naysayers wrong by positioning Biocon as an Indian pioneer in the lucrative biologic drugs market.
Inside the issue: Most Powerful Women in business
Here’s a sneak peek into the annual list, and more from the issue.
India-U.S. are natural synergistic partners: Kiran MazumdarShaw
Biocon CMD Kiran Mazumdar Shaw speaks to Fortune India on the sidelines of the USIBC India Ideas Summit; says U.S. and India are natural synergistic partners.
